Boehringer happy with first Phase III linagliptin diabetes results
This article was originally published in Scrip
Executive Summary
The first results from the Phase III programme of Boehringer Ingelheim's DPP-4 inhibitor linagliptin suggest that the drug has a favourable efficacy and safety profile, as was observed in Phase II trials, the company said.